{"id":"vancomycin-poc","safety":{"commonSideEffects":[{"rate":"5-25","effect":"Nephrotoxicity (acute kidney injury)"},{"rate":"1-5","effect":"Ototoxicity (hearing loss)"},{"rate":"25-90","effect":"Red man syndrome (flushing, pruritus, erythema)"},{"rate":"3-10","effect":"Phlebitis at infusion site"},{"rate":"1-5","effect":"Fever"},{"rate":"1-5","effect":"Chills"},{"rate":"1-5","effect":"Nausea and vomiting"}]},"_chembl":{"chemblId":"CHEMBL262777","moleculeType":"Small molecule","molecularWeight":"1449.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, blocking the cross-linking reactions catalyzed by transpeptidases. This prevents proper cell wall formation and integrity, leading to bacterial cell lysis and death. It is bactericidal and particularly effective against gram-positive organisms.","oneSentence":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:20.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)"},{"name":"Bacterial endocarditis"},{"name":"Clostridium difficile-associated diarrhea and colitis"},{"name":"Staphylococcal enterocolitis"},{"name":"Gram-positive bacterial infections in penicillin-allergic patients"}]},"trialDetails":[{"nctId":"NCT07221708","phase":"PHASE2, PHASE3","title":"Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-03-01","conditions":"Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium","enrollment":200},{"nctId":"NCT06794944","phase":"PHASE4","title":"Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-09","conditions":"Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection","enrollment":60},{"nctId":"NCT01232595","phase":"PHASE2","title":"Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10","conditions":"Moderate Clostridium Difficile Infection","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vancomycin (POC)","genericName":"Vancomycin (POC)","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture. Used for Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Bacterial endocarditis, Clostridium difficile-associated diarrhea and colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}